A few clinical studies have also found that CRC patients with KRAS codon 13 mutations might benefit from anti-EGFR therapies.[22,49] Our findings seem to support the potential benefits of anti-EGFR therapy for codon 13 mutations in CRC patients. Here, KRAS is linked to colorectal carcinoma.